<DOC>
	<DOCNO>NCT00339014</DOCNO>
	<brief_summary>The purpose study determine seven combination Zonisamide CR Bupropion SR give best weight loss safe well tolerate treatment obesity associate complication obesity diabetes . In previous study , combination zonisamide bupropion SR show effective weight loss compare either zonisamide , bupropion SR alone placebo . It think adjust dos drug , give zonisamide control release ( CR ) form increase dos slowly , weight loss less side effect attain .</brief_summary>
	<brief_title>Safety Efficacy Different Combinations Zonisamide-CR Plus Bupropion-SR Treat Uncomplicated Obesity</brief_title>
	<detailed_description>Over past year , knowledge pathway neural circuit sense body energy store increase dramatically . In particular , show melanocortin system , group neuronal circuit arcuate nucleus hypothalamus , `` final common pathway '' energy state signal , melanocortin signal necessary normal control food intake energy expenditure . Stimulation POMC neuron serotonergic dopaminergic agent result release α- , β- γ-MSH action prohormone convertase-2 consequent decrease appetite.A second counter-regulatory system inhibit POMC activation β-endorphin , bind mu-opioid receptor ( MOP-R ) act auto-inhibitory `` brake '' activity melanocortin circuit . Bupropion approve antidepressant block reuptake serotonin dopamine . This stimulate secretion α -MSH β-endorphin . α -MSH bind melanocortin receptor turn result appetite suppression increase energy expenditure . β-endorphin , however , bind mu-opioid receptor ( MOP-R ) inhibit activity melanocortin circuit . Zonisamide multiple effect may protect seizure , include blockade sodium channel , reduce voltage dependent inward ( T type ) calcium current , lead neuronal stabilization . In addition action , however , know increase 5-hydroxytryptophan dopamine level , simultaneously stimulate α -MSH release inhibit AGRP release . Thus , combination bupropion zonisamide stimulate melanocortin system block important feedback inhibitory pathway . The combination zonisamide 400 mg/day bupropion SR 300 mg/day show effective weight loss either monotherapy placebo subject uncomplicated obesity . The hypothesis current trial great efficacy improve tolerability achieve adjusting dos titration bupropion SR zonisamide , give zonisamide control release ( CR ) formulation .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Have body mass index ( BMI ) 30 43 kg/m2 Free clinically significant illness disease determine medical history physical examination Nonsmoker use tobacco nicotine product least 6 month prior screen Normotensive ( systolic &lt; 140 mm Hg ; diastolic &lt; 90 mm Hg ) . Antihypertensive medication allow exception adrenergic blocker , betablockers clonidine . Medical regimen must stable least 6 week LDL cholesterol &lt; 190 mg/dL triglyceride &lt; 400 mg/dL . Medications treatment dyslipidemia allow long medical regimen stable least 6 week Negative serum pregnancy test woman intact uterus Score &lt; 15 depression score &lt; 15 anxiety Hospital Anxiety Depression Scale ( HADS ) No clinically significant abnormality ECG Not eExcluded concomitant medication If female intact uterus , nonlactating , agree use effective contraception throughout study period 30 day discontinuation study drug . Able comply require study procedure schedule Able use access touch tone telephone speak read English Obesity know endocrine genetic origin Serious medical condition Serious psychiatric illness Active suicidal ideation ; score &gt; 2 Mood Assessment questionnaire A response Bipolar Disorder question indicate presence Bipolar Disorder Type I diabetes mellitus Type II diabetes mellitus require pharmacotherapy History alcohol drug abuse , current within 5 year History bulimia anorexia nervosa History surgical intervention obesity History seizure disorder predisposition seizure ( e.g. , history cerebrovascular accident , significant head trauma , brain surgery , skull fracture , subdural hematoma , alcohol withdrawal febrile seizure ) History hypersensitivity sulfonamide ( `` sulfa '' ) , bupropion , zonisamide History nephrolithiasis ( renal calculus ) History treatment bupropion SR ( Wellbutrin , Zyban ) zonisamide ( Zonegran ) within 12 month Use drug , herb , dietary supplement know significantly affect body weight participation weight loss management program within one month prior baseline Loss gain 4.0 kilo within 3 month Women child bear potential adhere acceptable form contraception Pregnant breastfeed woman Use investigational drug , device procedure within 30 day Participation previous clinical trial conduct Orexigen Therapeutics Planned surgical procedure impact conduct study Any condition opinion investigator make subject unsuitable inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>